Dopram

(Doxapram)

ApprovedSmall molecule

Dopram is one of 43 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

InfantsRecruiting

Chronic Obstructive Pulmonary DiseasePreclinical

Active, not recruiting

InfantsPhase 3

Recruiting

Competition

Competitive Landscape

120 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Dopram

HHikma Pharmaceuticals LLC

Approved

1 2

EXDENSUR

GGlaxo Dba Glaxosmithkline

Phase 3

2 3

Lunsekimig

Sanofi

Phase 3

3 4

Tozorakimab

AstraZeneca

Phase 3

2 5

CM310

KKeymed Biosciences Co.Ltd

Phase 3

1 6

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

2 7

Astegolimab

Roche

Phase 3

3 8

Titrated Oxygen

RRigshospitalet, Denmark

Phase 3

1 9

RLS-0071

RReAlta Life Sciences, Inc.

Phase 2

1 10

Calciferol

Jazz Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2034

Phase 3Recruiting

Infants

NCT04430790

Clinical

Trials by Indication[1]

Sedation1 trial

Doxapram as an Additive to Propofol Sedation in Sedation for ERCP

Completed·HHelsinki University Central Hospital·Phase 4·NCT02171910·50 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Doxapram Administration on Diaphragmatic Excursion in Mechanically Ventilated Patients With Chronic Obstructive Pulmonary Disease Undergoing Spontaneous Breathing Trial

Recruiting·—··NCT07022704·35 enrolled

Premature Infants1 trial

Dosing Chart for Calculating the First Dose of Doxapram in Premature Infants

Completed·JJean Michel Hascoet·Phase 4·NCT00389909·85 enrolled

Infants1 trial

Doxapram Therapy in Preterm Infants (DOXA Trial)

Recruiting·EErasmus Medical Center·Phase 3·NCT04430790·396 enrolled

Unspecified1 trial

The Effect and Mechanism of Respiratory Stimulant Doxapram on Facilitating Emergence

Unknown status·GGeneral Hospital of Ningxia Medical University·N/A·NCT02820025·40 enrolled

Regulatory

FDA Approval Timeline[4]

Jan 1, 1982

DOPRAM

NDA NDA014879

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Doxapram. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Doxapram compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Doxapram. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA014879). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Hikma Pharmaceuticals LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHikma Pharmaceuticals LLC

Dopram

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2034

Trials by Indication[1]

Sedation1 trial

Chronic Obstructive Pulmonary Disease1 trial

Premature Infants1 trial

Infants1 trial

Unspecified1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News